Mark T Fillmore1, Craig R Rush, Lon Hays. 1. Department of Psychology, University of Kentucky, Lexington, KY 40506-0044, USA. fillmore@uky.edu
Abstract
AIMS: This study examined dose-response effects of oral cocaine on the inhibitory control of behavior in adult cocaine users using two different behavioral models of inhibitory control. DESIGN: Adults (n = 12) with a history of cocaine use performed the stop-signal and cue-dependent go-no-go task to measure inhibitory control of behavior in response to a range of oral cocaine HCl doses (0, 100, 200 and 300 mg). FINDINGS: Although both tasks showed cocaine-induced facilitation of inhibitory control, dose-response functions differed depending on the measures. The stop-signal measure revealed a quadratic dose-response function and the cued go-no-go measure showed a more orderly, linear improvement as a function of dose. CONCLUSIONS: The evidence suggests a two-phasic dose-response in which facilitating effects of stimulant drugs on inhibitory control might be limited to a range of intermediate doses, above which improvement is no longer evident and impairing effects could possibly emerge.
AIMS: This study examined dose-response effects of oral cocaine on the inhibitory control of behavior in adult cocaine users using two different behavioral models of inhibitory control. DESIGN: Adults (n = 12) with a history of cocaine use performed the stop-signal and cue-dependent go-no-go task to measure inhibitory control of behavior in response to a range of oral cocaineHCl doses (0, 100, 200 and 300 mg). FINDINGS: Although both tasks showed cocaine-induced facilitation of inhibitory control, dose-response functions differed depending on the measures. The stop-signal measure revealed a quadratic dose-response function and the cued go-no-go measure showed a more orderly, linear improvement as a function of dose. CONCLUSIONS: The evidence suggests a two-phasic dose-response in which facilitating effects of stimulant drugs on inhibitory control might be limited to a range of intermediate doses, above which improvement is no longer evident and impairing effects could possibly emerge.
Authors: Martin Zack; Tracy M Woodford; Anne M Tremblay; Lindsay Steinberg; Laurie A Zawertailo; Usoa E Busto Journal: Neuropsychopharmacology Date: 2010-10-06 Impact factor: 7.853
Authors: Deanna M Barch; Todd S Braver; Cameron S Carter; Russell A Poldrack; Trevor W Robbins Journal: Schizophr Bull Date: 2008-11-14 Impact factor: 9.306
Authors: Rita Z Goldstein; A D Bud Craig; Antoine Bechara; Hugh Garavan; Anna Rose Childress; Martin P Paulus; Nora D Volkow Journal: Trends Cogn Sci Date: 2009-08-27 Impact factor: 20.229